CUTAQUIG 165 mg/ml solution for injection
*Company:
Octapharma LtdStatus:
UpdatedLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 27 October 2025
File name
Cutaquig PIL IE 20250601.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
MAH address has changed
Updated on 27 October 2025
File name
Cutaquig SmPC IE 20251017.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
MAH address has changed
Updated on 22 November 2023
File name
20231108_81x_PIL_IE_09.08_en.pdf
Reasons for updating
- Removal of Black Inverted Triangle
- Change to date of revision
Updated on 22 November 2023
File name
20231108_81x_PIL_IE_09.08_en.pdf
Reasons for updating
- Removal of Black Inverted Triangle
- Change to date of revision
Updated on 22 November 2023
File name
20231117_81x_SPC_IE_09.08_en.pdf
Reasons for updating
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 22 November 2023
File name
20231117_81x_SPC_IE_09.08_en.pdf
Reasons for updating
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 25 August 2023
File name
20230822_81x_SPC_IE_08.07_en.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 25 August 2023
File name
20230822_81x_PIL_IE_08.07_en.pdf
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Updated information on infusion rate
Updated safety information - side effects
Updated on 25 August 2023
File name
20230822_81x_SPC_IE_08.07_en.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 06 June 2022
File name
Cutaquig SmPC IE 20220505.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 04 May 2022
File name
Cutaquig PIL IE 20220318.pdf
Reasons for updating
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 04 May 2022
File name
Cutaquig SmPC IE 20220318.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 15 December 2021
File name
Cutaquig IE PIL 20210611.pdf
Reasons for updating
- New PIL for new product
Updated on 15 December 2021
File name
Cutaquig SPC IE 20210420.pdf
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 15 December 2021
File name
Cutaquig SPC IE 20210420.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Octapharma Ltd
Address:
MAH: Octapharma (IP) SPRL, Allée de la Recherche 65, 1070 Anderlecht, Belgium, (Local Agent: Octapharma Ltd, Glassworks House, 32 Shudehill, Manchester, Lancashire, M4 1EZ)Medical Information E-mail:
medinfo.uk@octapharma.comTelephone:
+44 (0)161 837 3770Website:
https://www.octapharma.co.uk